The analyst rating for MEDBOT-B (02252.HK) was given as Overweight by JPMorgan due to several key factors. The company's core product, Toumai, has shown strong sales momentum, with over 200 units ordered and an increase of approximately 20 orders since late January 2026. This growth alleviates market concerns about the sustainability of its sales. Additionally, MEDBOT-B has expanded its market coverage to over 50 countries and regions, with significant orders coming from both emerging markets like India and Brazil, as well as developed markets such as Spain and Australia. This achievement positions MEDBOT-B as a leading domestic enterprise in China, allowing it to benefit from the trend of import substitution. Consequently, JPMorgan set a target price of $41 for the stock.
